Clinical Trial Update: Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating imatinib mesylate in patients with refractory or relapsed ovarian epithelial cancer, fallopian tube cancer, primary per…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Ovarian Tumor of Low Malignant Potential
• Peritoneal Cancer

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED